These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Hypersociability in the Angelman syndrome mouse model. Stoppel DC; Anderson MP Exp Neurol; 2017 Jul; 293():137-143. PubMed ID: 28411125 [TBL] [Abstract][Full Text] [Related]
4. Assessing the requirements of prenatal UBE3A expression for rescue of behavioral phenotypes in a mouse model for Angelman syndrome. Sonzogni M; Zhai P; Mientjes EJ; van Woerden GM; Elgersma Y Mol Autism; 2020 Sep; 11(1):70. PubMed ID: 32948244 [TBL] [Abstract][Full Text] [Related]
5. Neuronal overexpression of Ube3a isoform 2 causes behavioral impairments and neuroanatomical pathology relevant to 15q11.2-q13.3 duplication syndrome. Copping NA; Christian SGB; Ritter DJ; Islam MS; Buscher N; Zolkowska D; Pride MC; Berg EL; LaSalle JM; Ellegood J; Lerch JP; Reiter LT; Silverman JL; Dindot SV Hum Mol Genet; 2017 Oct; 26(20):3995-4010. PubMed ID: 29016856 [TBL] [Abstract][Full Text] [Related]
6. Generation and Characterization of a Novel Angelman Syndrome Mouse Model with a Full Deletion of the Syding LA; Kubik-Zahorodna A; Nickl P; Novosadova V; Kopkanova J; Kasparek P; Prochazka J; Sedlacek R Cells; 2022 Sep; 11(18):. PubMed ID: 36139390 [TBL] [Abstract][Full Text] [Related]
7. Towards a therapy for Angelman syndrome by targeting a long non-coding RNA. Meng L; Ward AJ; Chun S; Bennett CF; Beaudet AL; Rigo F Nature; 2015 Feb; 518(7539):409-12. PubMed ID: 25470045 [TBL] [Abstract][Full Text] [Related]
8. Truncation of Ube3a-ATS unsilences paternal Ube3a and ameliorates behavioral defects in the Angelman syndrome mouse model. Meng L; Person RE; Huang W; Zhu PJ; Costa-Mattioli M; Beaudet AL PLoS Genet; 2013; 9(12):e1004039. PubMed ID: 24385930 [TBL] [Abstract][Full Text] [Related]
9. Altered ultrasonic vocalization and impaired learning and memory in Angelman syndrome mouse model with a large maternal deletion from Ube3a to Gabrb3. Jiang YH; Pan Y; Zhu L; Landa L; Yoo J; Spencer C; Lorenzo I; Brilliant M; Noebels J; Beaudet AL PLoS One; 2010 Aug; 5(8):e12278. PubMed ID: 20808828 [TBL] [Abstract][Full Text] [Related]
10. A behavioral test battery for mouse models of Angelman syndrome: a powerful tool for testing drugs and novel Sonzogni M; Wallaard I; Santos SS; Kingma J; du Mee D; van Woerden GM; Elgersma Y Mol Autism; 2018; 9():47. PubMed ID: 30220990 [TBL] [Abstract][Full Text] [Related]
11. Genotype-Phenotype Correlations in Angelman Syndrome. Yang L; Shu X; Mao S; Wang Y; Du X; Zou C Genes (Basel); 2021 Jun; 12(7):. PubMed ID: 34203304 [TBL] [Abstract][Full Text] [Related]
12. Towards an understanding of Angelman syndrome in mice studies. Yang X J Neurosci Res; 2020 Jun; 98(6):1162-1173. PubMed ID: 31867793 [TBL] [Abstract][Full Text] [Related]
13. Characterization and structure-activity relationships of indenoisoquinoline-derived topoisomerase I inhibitors in unsilencing the dormant Lee HM; Clark EP; Kuijer MB; Cushman M; Pommier Y; Philpot BD Mol Autism; 2018; 9():45. PubMed ID: 30140420 [TBL] [Abstract][Full Text] [Related]
14. Enhanced Nociception in Angelman Syndrome Model Mice. McCoy ES; Taylor-Blake B; Aita M; Simon JM; Philpot BD; Zylka MJ J Neurosci; 2017 Oct; 37(42):10230-10239. PubMed ID: 28931574 [TBL] [Abstract][Full Text] [Related]
15. Ube3a reinstatement identifies distinct developmental windows in a murine Angelman syndrome model. Silva-Santos S; van Woerden GM; Bruinsma CF; Mientjes E; Jolfaei MA; Distel B; Kushner SA; Elgersma Y J Clin Invest; 2015 May; 125(5):2069-76. PubMed ID: 25866966 [TBL] [Abstract][Full Text] [Related]
16. A novel UBE3A sequence variant identified in eight related individuals with neurodevelopmental delay, results in a phenotype which does not match the clinical criteria of Angelman syndrome. Geerts-Haages A; Bossuyt SNV; den Besten I; Bruggenwirth H; van der Burgt I; Yntema HG; Punt AM; Brooks A; Elgersma Y; Distel B; Valstar M Mol Genet Genomic Med; 2020 Nov; 8(11):e1481. PubMed ID: 32889787 [TBL] [Abstract][Full Text] [Related]
19. UBE3A reinstatement as a disease-modifying therapy for Angelman syndrome. Elgersma Y; Sonzogni M Dev Med Child Neurol; 2021 Jul; 63(7):802-807. PubMed ID: 33543479 [TBL] [Abstract][Full Text] [Related]
20. Understanding the pathogenesis of Angelman syndrome through animal models. Jana NR Neural Plast; 2012; 2012():710943. PubMed ID: 22830052 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]